Last reviewed · How we verify
C-peptide proinsulin ratio
At a glance
| Generic name | C-peptide proinsulin ratio |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) (PHASE2)
- Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus (PHASE2)
- Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
- Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (PHASE1)
- Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes (PHASE1, PHASE2)
- Effect of Splitting Mealtime Insulin Doses After Mixed Meals High in Fat and Protein (PHASE4)
- New Onset Type 1 Diabetes: Role of Exenatide (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C-peptide proinsulin ratio CI brief — competitive landscape report
- C-peptide proinsulin ratio updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI